Key Takeaways & Executive Findings
- •• The original article's author affiliation has been corrected to accurately reflect the institutional association. • The correction ensures proper attribution and compliance with academic publishing standards. • The study investigates the role of HSPA8 in stabilizing CLPP protein, which regulates mitochondrial autophagy in cisplatin-resistant ovarian cancer cells. • This research provides insights into potential therapeutic targets for overcoming cisplatin resistance in ovarian cancer.
Abstract
This corrigendum corrects the affiliation of the authors in the original article. The affiliation has been changed from 'Cancer Hospital Affiliated to Zhengzhou University' to 'The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital'.
1. Introduction
This corrigendum addresses an error in the originally published article titled 'HSPA8-mediated stability of the CLPP protein regulates mitochondrial autophagy in cisplatin-resistant ovarian cancer cells' (Acta Biochim Biophys Sin 2024, 56(3): 356–365). The authors' affiliation was incorrectly listed as 'Cancer Hospital Affiliated to Zhengzhou University'. The correct affiliation is 'The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital'. This correction is essential for accurate attribution and reflects the authors' true institutional affiliations.
The original study explores the molecular mechanisms underlying cisplatin resistance in ovarian cancer, focusing on the role of HSPA8 in stabilizing the CLPP protein, which in turn regulates mitochondrial autophagy. Understanding these pathways is critical for developing novel therapeutic strategies to overcome drug resistance and improve patient outcomes.
Loading authentic research manuscript (Pages 1–5)...
Xinxin Kou, Xiaoxia Yang, Zheng Zhao, Lei Li (2026). HSPA8-mediated stability of the CLPP protein regulates mitochondrial autophagy in cisplatin-resistant ovarian cancer cells. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2023246
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the main topic of the original article?
The original article investigates how HSPA8-mediated stability of the CLPP protein regulates mitochondrial autophagy in cisplatin-resistant ovarian cancer cells.
What correction is made in this corrigendum?
The correction changes the affiliation of the authors from 'Cancer Hospital Affiliated to Zhengzhou University' to 'The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital'.
Why is this correction important?
Accurate affiliation is crucial for proper attribution, institutional recognition, and maintaining the integrity of the scientific record.
What are the potential clinical implications of the original research?
The research may lead to new therapeutic targets to overcome cisplatin resistance in ovarian cancer, potentially improving treatment efficacy and patient survival.
Where was the original article published?
The original article was published in Acta Biochimica et Biophysica Sinica, volume 56, issue 3, pages 356-365, with DOI 10.3724/abbs.2023246.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.